Publications

  1. Hitchcock KE, Nichols RC, Morris CG, Bose D, Hughes SJ, Stauffer JA, Celinski SA, Johnson EA, Zaiden RA, Mendenhall NP, Rutenberg MS. Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. World J Gastrointest Surg. 2017 Apr 27; 9: (4)103-108.
    View PubMed
  2. Mody K, Feldman Rebecca, Reddy Sandeep K., Reynolds GA, Mcmillan JM, Johnson EA. PD-1/PD-L1 expression and molecular associations in HPB malignancies. Journal of Clinical Oncology.2016;34:(suppl 4S)Abstr 289.
  3. Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R, Mayo Phase, California Consortium. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011 Oct; 6(10):1757-60.
    View PubMed
  4. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1; 26(31):5043-51. Epub 2008 Sep 22.
    View PubMed
  5. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer. 2008 May; 60 (2):200-7 Epub 2007 Nov 28
    View PubMed
  6. Perez EA, Geoffroy FJ, Hillman S, Johnson EA, Farr GH Jr, Tazelarr HD, Hatfield AK, Krook JE, Maillard JA, Levitt R, Marks RS. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer. 2004 Jun; 44(3):347-53.
    View PubMed
  7. Johnson E, Lake D, Herndon JE, Box JW, Lynch TJ, Green MR. Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. Am J Clin Oncol. 2004 Feb; 27(1):19-23.
    View PubMed
  8. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W Jr, Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1998 Nov; 16(11):3524-7.
    View PubMed
  9. Gryn J, Johnson E, Goldman N, Devereux L, Grana G, Hageboutros A, Fernandez E, Constantinou C, Harrer W, Viner E, Goldberg J. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplant. 1997 Feb; 19(3):221-6.
    View PubMed
  10. Order SE, Siegel JA, Principato R, Zeiger LE, Johnson E, Lang P, Lustig R, Wallner PE. Selective tumor irradiation by infusional brachytherapy in nonresectable pancreatic cancer: a phase I study. Int J Radiat Oncol Biol Phys. 1996 Dec 1; 36(5):1117-26.
    View PubMed
  11. Dewald GW, Stallard R, Bader PI, Chen K, Zenger-Hain J, Harris CJ, Higgins R, Hirsch B, Hsu WT, Johnson E, Kubic V, Kurczynski TW, Malone JM, McCorquodale DJ, Meilinger K, Meisner LF, Moore JW, Schwartz S, Siembieda S, Storto PD, Vance G, Van Tuinen P, Wiktor A, Yung JF. Toward quality assurance for metaphase FISH: a multicenter experience. Am J Med Genet. 1996 Oct 28; 65(3):190-6.
    View PubMed
  12. Dewald G, Stallard R, Bader PI, Chen K, Zenger-Hain J, Harris CJ, Higgins R, Hirsch B, Hsu WT, Johnson E, Kubic V, Kurczynski TW, Malone JM, McCorquodale DJ, Meilinger K, Meisner LF, Moore JW, Schwartz S, Siembieda S, Storto PD, Vance G, Van Tuinen P, Wiktor A, Yung JF. Toward quality assurance for metaphase FISH: a multi-center experience. Am J Med Genet. 1996 Sep 6; 64(4):539-45.
    View PubMed
  13. Order SE, Siegel JA, Principato R, Zeiger LS, Johnson E, Lang P, Lustig R, Kroprowski C, Wallner PE. Preliminary experience of infusional brachytherapy using colloidal 32P. Ann Acad Med Singapore. 1996 May; 25(3):347-51.
    View PubMed
  14. Order SE, Siegel JA, Lustig RA, Principato R, Zeiger LS, Johnson E, Zhang H, Lang P, Pilchik NB, Metz J, et al. A new method for delivering radioactive cytotoxic agents in solid cancers. Int J Radiat Oncol Biol Phys. 1994 Oct 15; 30(3):715-20.
    View PubMed
  15. Order SE, Siegel JA, Lustig RA, Principato R, Zeiger LS, Johnson EA, Zhang H, Lang P, Wallner PE. Infusional brachytherapy in the treatment of nonresectable pancreatic cancer: A new radiation modality (Preliminary report of the Phase I study). Antibody Immunoconjugates and Radiopharmaceuticals. 1994; 7(1):11-27.
  16. Gryn J, Goldberg J, Johnson E, Siegel J, Inzerillo J. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol. 1993 Feb; 16(1):43-6.
    View PubMed
  17. Raschko JW, Johnson EA, Ueno W, Woolley PV, Treat J. Continuous infusion 5-fluorouracil with bolus adriamycin and mitomycin and low-dose cisplatin (FAMP) in the treatment of metastatic gastric carcinoma: an evaluation of efficacy and toxicity. Cancer Invest. 1991; 9(1):49-51.
    View PubMed